To the Editor:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), is characterized by a wide spectrum of disease encompassing asymptomatic carriage, mild to severe upper respiratory tract illness that can evolve into respiratory failure, or rapidly progressing severe viral pneumonia with acute respiratory distress syndrome. Disease severity depends on viral strain, and host risk factors have been identified such as age and male sex. In addition, an excessive immune response has been identified in patients showing a cytokine storm associated with acute respiratory distress syndrome.[@bib1] Various immunosuppressive drugs, including IL-6 blockers or Janus kinases (JAK)-signal transducer and activator of transcription signaling inhibitors, have been suggested for the treatment of SARS-COV-2 infection,[@bib2] whereas additional clinical trials are evaluating the use of recombinant IFN to foster host antiviral response (clinical trials [NCT04315948](NCT04315948){#intref0010} and [NCT04293887](NCT04293887){#intref0015}). Type I IFNs (IFN-I) are major components of the innate immune system and represent critical antiviral molecules.[@bib3] To date, IFN-I response has not been evaluated in patients with COVID-19 and its contribution to the viral control and inflammation is unknown.

In this study, we assessed the kinetics of plasma IFN-I in patients with COVID-19 with a spectrum of severity degree. This study was approved by an ethical committee for biomedical research (Comité de Protection des Personnes HCL) (see text and this article's Methods section in the Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0020}).

First, we explored 3 patients issued from the first COVID cluster diagnosed in France (Les Contamines, Haute Savoie, France) in February 2020. We took advantage of the new digital ELISA technology single-molecule arrays (Simoa)[@bib4] and analyzed the kinetics of plasma inflammatory cytokines. IL-6, C-reactive protein (CRP), and IFN-γ--induced protein 10 (IP-10) were elevated in the 2 symptomatic patients (patients 1 and 3) (see [Fig E1](#figE1){ref-type="fig"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0025}). Strikingly, no IFN-α2 was detectable in these 2 patients. In contrast, IL-6, CRP, and IP-10 remained low during the hospital isolation stay for the asymptomatic individual and a significant elevation in plasmatic IFN-α2 was observed. Viral loads were low, with no obvious quantitative difference between all 3 patients.

We further explored a larger cohort of 26 critically ill patients with COVID from 1 of the intensive care unit at Hospices Civils de Lyon (Lyon, France). Of note, all the patients were treated with standard of care and none received antiviral or immunotherapies. Considering the first 28 days of infection, more than half of critically ill patients required invasive mechanical ventilation (14 of 26). We observed that patients demonstrated a peak in IFN-α2 at day 8 to 10 of symptom onset corresponding to the viral replication phase, which decreased overtime to low but still detectable IFN-α2 concentrations. Conversely, a subset of patients (n = 5 \[19%\]) presented with sustained abrogation of IFN-I production ([Fig 1](#fig1){ref-type="fig"} , *A*). Simoa IFN-α2 measurement demonstrated a positive correlation with IFN-stimulated genes (see [Fig E2](#figE2){ref-type="fig"}, *A*, in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0030}) as already shown in viral infections.[@bib5] We noticed a strong proinflammatory response in all cases (CRP, IL-6, or IP-10), which started early and remained positive, whereas IFN-I response decreased after day 10 of infection ([Fig 1](#fig1){ref-type="fig"}, *B-D*). Patients with no IFN-α production presented poorer outcome, all of them requiring invasive ventilation (n = 5 of 5) and showing a longer intensive care unit stay ([Table I](#tbl1){ref-type="table"} ). The viral load tended to be higher in IFN-negative patients with COVID-19 at disease diagnosis. IFN-β and IFN-λ were undetectable, whereas low amount of IFN-γ was detected in all patients with no evident link with IFN-α2 level (see [Fig E2](#figE2){ref-type="fig"}, *B-D*).Fig 1Plasma IFN-α2, IL-6, CRP, and IP-10 concentrations in COVID-19 critically ill patient cohort (n = 26). **A,** Plasma IFN-α concentrations (fg/mL) were determined by single-molecule array (Simoa). Fit Loess curve represents local polynomial regression performed with Loess method. CI at 95% was indicated (orange area). **B-D,** CRP (µg/mL), IL-6, and IP-10 (pg/mL) concentrations were measured using a multiplexed assay with the Ella platform. Normal values for healthy volunteers were indicated by grey area. Vertical bar indicates the median delay between symptom onset and intensive care unit admission.Table IClinical characteristics of patients with COVID-19 in intensive care unitClinical featureIFN-negative (n = 5)IFN-positive (n = 21)*P* valueAge (y), median (min-max)81 (63-83)74 (28-91).696Sex (male), n (%)5 (100)18 (86)1.000Delay between symptom onset and ICU admission (d)7 (1-11)7 (0-15).769Bacterial coinfection during ICU stay, n (%)3 (60)7 (33).3402Diabetes, n (%)1 (20)3 (14).5043Chronic obstructive pulmonary disease, n (%)0 (0)3 (14)1.000Cardiovascular disease, n (%)2 (40)9 (43)1.000Hypertension, n (%)3 (60)7 (33).3402Cancer, n (%)1 (20)3 (14)1.000Active smokers, n (%)0 (0)1(5)1.000BMI \>30 kg/m^2^, n (%)3 (60)8 (38).620Biological feature, median (min-max) Viral load at diagnosis (Ct), median (min-max)20.9 (18-28.2)25.1 (16.1-38.0).172 Outcome, n (%) Standard oxygen therapy only0 (0)5 (24).5451 High flow oxygen therapy only0 (0)7 (33).278 Invasive ventilation at any time during ICU stay5 (100)9 (42)**.0425** ICU length of stay, median (min-max)20 (7-30)5 (0-35).0503 Mortality at day 28 after symptom onset, n (%)2 (40)8 (38)1.000[^3][^4][^5]

Taken together, our data demonstrate a heterogeneous pattern of IFN-α response in patients with COVID-19, with IFN-I response being impaired in about 1 of 5 of critically ill patients. This defective innate immune response may be associated with a poor outcome. In murine models of SARS-CoV-1 infection, delayed IFN-I production is associated with lung lesions and fatal outcome whereas early administration of IFN-I prevents lung lesions.[@bib6] SARS-CoV-2 displays a better sensitivity to IFN-I *in vitro* compared with SARS-CoV-1 in infected cell lines.[@bib7] Therefore, early administration of IFN-α2 might be promising for patients with COVID-19, especially in those who demonstrate a defective IFN response. The timing of IFN exposition may be critical to control the virus and avoid immunopathogenesis. Channappanavar et al[@bib6] have shown that delayed IFN-I expression can be detrimental in mice in the context of SARS-CoV-1 infection.[@bib6] Our data suggest that screening patients for IFN production is instrumental to select those who could benefit from early intervention with IFN. Following day 10, IL-6 remains increased whereas IFN-α tapered. This kinetics highlight that cytokine inhibitors could be helpful at the second phase of the disease following IFN-I decrease. Viral characteristic or individual genetic susceptibility should be explored to understand the defect of IFN-α production in some patients with COVID. Some IFN-α2--positive patients also experienced fatal outcome, highlighting the multifactorial causes of disease severity. We acknowledge limitations of this study, related to the small number of included patients and the technical limitation for the measurement of IFN-β and IFN-λ, in this proof-of-concept study.

Here, we provide new arguments for an early intervention with recombinant IFN-α2 and we also highlight the window of opportunity for immunosuppressors at the second phase of the disease, opening new avenues in COVID-19 therapies.

Methods {#appsec1}
=======

Clinical characteristics of nonsevere patients with COVID {#appsec1.1}
---------------------------------------------------------

We explored the first 3 SARS-COV-2--positive patients diagnosed in France (Les Contamines, France) in February 2020.

Patient 1: One week before the first positive test result, a 46-year-old man developed mild signs and symptoms (fever, dry cough, asthenia, chills). Monitoring of viral load from consecutive nasopharyngeal swabs was performed ([Fig E1](#figE1){ref-type="fig"}, *E*). He had a benign evolution.

Patient 2: A 56-year-old woman was asymptomatic and did not develop any sign or symptom despite the detection of SARS-CoV-2 from nasopharyngeal swabs during several consecutive days ([Fig E1](#figE1){ref-type="fig"}, *E*).

Patient 3: A high-risk contact (a 54-year-old man) initially negative for SARS-CoV-2 developed fever and cough with respiratory crackles at auscultation on the fifth day of hospital isolation. A bilateral interstitial syndrome at the computed tomography scan with bilateral ground-glass opacification was predominant on the left. SARS-CoV-2 was detected from endotracheal aspirates, and all nasopharyngeal swabs were always negative. The daily follow-up revealed a short-lasting excretion with only 2 successive endotracheal aspirates ([Fig E1](#figE1){ref-type="fig"}, *E*).

For these 3 patients, no other respiratory pathogens were detected. These patients did not need oxygenation, nor antibiotics, steroids, or antiviral agents.

Patients {#appsec1.2}
--------

Plasma samples and Paxgene tubes were collected from patients with COVID-19 hospitalized in the University Hospital of Lyon (Hospices Civils de Lyon), France. Diagnosis of COVID-19 was confirmed in all patients by RT-PCR.

All critically ill patients, admitted to intensive care unit, were included in the MIR-COVID study. This study was registered to the French National Data Protection Agency under the number 20-097 and was approved by an ethical committee for biomedical research (*Comité de Protection des Personnes HCL*) under the number N°20-41. In agreement with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law n°78-17 on 06/01/1978 and Décret n°2019-536 on 29/05/2019), we obtained consent from each patient or his next of kin.

Plasma protein quantification {#appsec1.3}
-----------------------------

Plasma IFN-α concentrations (fg/mL) were determined by single-molecule array (Simoa) using a commercial kit for IFN-α2 quantification (Quanterix, Lexington, Mass) on plasma samples of patients with COVID-19. The assay was based on a 3-step protocol using an HD-1 Analyzer (Quanterix). IL-6, CRP, and IP-10 concentrations were measured using a multiplexed assay with the Ella platform (Protein simple, San Jose, Calif), according to manufacturer's instructions.

Plasma IFN-γ and IFN-β have been quantified using the Ella platform (Protein simple), according to manufacturer's instructions. Plasma IL28A/B and IL-29 (type III IFN) have been quantified by ELISA (PBL Laboratories, Piscataway, NJ).

IFN score assessment {#appsec1.4}
--------------------

RNA was extracted from whole blood contained in Paxgene tubes (Kit PreAnalytix, Qiagen, Hilden, Germany) and quantified by spectrophotometric assay (Nanodrop 2000, Thermo Scientific, Waltham, Mass). RNA integrity was then evaluated by Agilent RNA microarray (Agilent Technologies, Santa Clara, Calif). mRNA quantification of 6 IFN-stimulated genes (IFN-α--inducible protein 27, IFN-induced protein 44 like, IFN-Induced Protein With Tetratricopeptide Repeats 1, ISG15 Ubiquitin Like Modifier, Radical S-Adenosyl Methionine Domain Containing 2, and Sialic Acid Binding Ig Like Lectin 1 and 3 housekeeping genes---*Actin Beta*, *Hypoxanthine Phosphoribosyltransferase 1*, and *RNA Polymerase II Subunit A*) was performed using nanostring technology (Nanostring Technologies, Seattle, Wash). Data standardization was obtained using the geometric mean of internal control and housekeeping genes count number. IFN score was calculated as previously described.[@bib8]

Virus quantification load {#appsec1.5}
-------------------------

Viral load was quantified from nasopharyngeal swabs or endotracheal aspirates. RNA extraction was performed by the automated NucliSENS easyMAG (BioMérieux, Marcy l'Etoile, France) using manufacturer's instructions. A 25-μL reaction contained 5 μL of RNA, 12.5 μL of 2× reaction buffer provided with the Superscript III 1-step RT-PCR system with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany; containing 0.4 mM of each dNTPs and 3 mM magnesium sulfate), 1 μL of reverse transcriptase/Taq mixture from the kit, and 0.4 μL of a 50 mM magnesium sulfate solution (Invitrogen). Thermal cycling was performed at 55°C for 20 minutes for reverse transcription, followed by 95°C for 3 minutes and then 50 cycles of 95°C for 15 seconds, 58°C for 30 seconds, on the QuantStudio 5 rtPCR Systems (Thermo Fisher Scientific, Waltham, Mass). Primer and probe used are based on the Institut Pasteur protocol (Paris, France).[@bib9]

Statistical analysis {#appsec1.6}
--------------------

*P* values were calculated using Mann-Whitney test for quantitative values and using Fisher-exact test for qualitative ones. Fig E1Plasma cytokine levels and viral load in 3 SARS-COV-2--positive patients diagnosed in France. **A,** Plasma IFN-α concentrations (fg/mL) were determined by single-molecule array (Simoa). **B-D,** IL-6, CRP, and IP-10 concentrations were measured using a multiplexed assay with the Ella platform. **E,** Viral load is represented as cycle threshold of IP2 RT-quantitative PCR using assay designed by Pasteur Institut in Paris.Fig E2IFN score and plasma IFN-β, IFN-λ, and IFN-γ concentrations in COVID-19 critically ill patient cohort (n = 26). **A,** IFN score is a transcriptional signature defined by 6 IFN-stimulated genes quantified using nanostring technology and obtained from Paxgene tubes in 4 patients with COVID-19. **B-D,** Normal values for healthy volunteers were indicated by gray area. Vertical bar indicates median delay between symptom onset and intensive care unit admission. Concentrations of IFN-γ were quantified in only 16 of 26 patients because of lack of material.
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